Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.70 |
| ▸ | MET | P08581 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 8/20 | 0.63 |
| ▸ | ITK | Q08881 | 2/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | CDK7 | P50613 | 5/20 | 0.58 |
| ▸ | CCNH | P51946 | 5/20 | 0.58 |
| ▸ | ULK1 | O75385 | 2/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | CDK9 | P50750 | 2/20 | 0.57 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CCNK | O75909 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179588 | 1.00 | ALK (0.70) | ALKMETEGFRITKJAK3 | |
| SCHEMBL17766076 | 0.90 | EGFR (0.62) | ALKMETEGFRITKJAK3 | |
| SCHEMBL17766075 | 0.90 | EGFR (0.62) | ALKMETEGFRITKJAK3 | |
| SCHEMBL12179627 | 0.88 | EGFR (0.65) | ALKMETEGFRITKCDK7 | |
| SCHEMBL2594581 | 0.86 | ALK (0.76) | ALKMETEGFRULK1MAPK8 | |
| SCHEMBL17792825 | 0.84 | EGFR (0.70) | EGFRITKJAK3CDK7CCNH | |
| SCHEMBL14973233 | 0.81 | ALK (0.81) | ALKMETEGFRULK1MAPK8 | |
| SCHEMBL14983024 | 0.81 | ALK (0.81) | ALKMETEGFRULK1MAPK8 | |
| SCHEMBL16385544 | 0.80 | EGFR (0.65) | ALKMETEGFR | |
| SCHEMBL22144557 | 0.79 | ULK1 (0.81) | ALKMETEGFRCDK7ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885MET 8/4885EGFR 1/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | ALK 911/4885MET 8/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.